IMV News and Press, IMV Inc. From 04/07/21

The two companies agreed on final design of the new Phase 2B study Patient population and clinical endpoints aligned with FDA guidance for potential path to accelerated approval IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a ...

IMV to leverage Mr. Kuvalanka’s industry expertise as it advances its lead immunotherapy toward potential registration and commercialization Company advancing novel immunotherapies in oncology and infectious diseases built on its proprietary DPX platform with no...

Image source: The Motley Fool. IMV Inc. (NASDAQ: IMV) Q4 2020 Earnings Call Mar 17, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: IMV Inc. (IMV) Q4 2020 Earnings Call Transcript

Gainers: Takung Art (TKAT) +122%.Zhongchao (ZCMD) +52%.Oriental Culture (OCG) +43%.Integrated Media Technology (IMTE) +43%.Immatics (IMTX) +33%.Puyi (PUYI) +29%.Willis Lease Finance (WLFC) +24%.Lipocine (LPCN) +24%.Liquid Media (YVR) +21%.Sigma Labs (SGLB) +20%.Losers: Sun...

IMV Inc. (IMV) Q4 2020 Earnings Conference Call March 17, 2021 08:00 ET Company Participants Pierre Labbé - Chief Financial Officer Fred Ors - Chief Executive Officer Joanne Schindler - Chief Medical Officer Andrew Hall - Chief Business Officer Conference Call Participants Tom Shrader - ...

Gainers: Zhongchao (ZCMD) +53%, Immatics (IMTX) +42%, Lipocine (LPCN) +23%, FSD Pharma (HUGE) +18%, Nabriva Therapeutics (NBRV) +18%.Losers: SunLink Health Systems (SSY) -28%, Rubius Therapeutics (RUBY) -17%, CHF Solutions CHFS&...

The following slide deck was published by IMV Inc. in conjunction with their 2020 Q4 earnings call. For further details see: IMV Inc. 2020 Q4 - Results - Earnings Call Presentation

IMV (IMV): FY GAAP EPS of -C$0.58 misses by $0.18.Cash and cash equivalents of C$46.4MPress Release For further details see: IMV EPS misses by $0.18

Phase 2B clinical trial in patients with relapsed /refractory DLBCL expected to be initiated in Q2 2021 following guidance received from the FDA Maveropepimut-S (DPX-Survivac) in combination with Merck’s Keytruda ® (pembrolizumab) and low dose cyclophosphamide ...

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, announced today that it will hold a conference call and webcast on Wednesday, March 17, 2021 at 8:00 a.m. Ea...